Research
Hormonal
Estrogen deficiency during menopause leads to dysregulated lipid metabolism, characterized by increased LDL-C, increased triglycerides, and altered HDL subfractions, thereby increasing cardiovascular disease risk.
Understand that the drop in estrogen after menopause naturally raises your LDL cholesterol and triglycerides while lowering protective HDL. This increases your risk of heart disease. Managing this through diet (healthy fats, fiber) and potentially medical intervention is crucial for long-term heart health.
GoodSupportsHIGH confidence
Women are at a higher risk of developing CVDs after menopause due to estrogen deficiency and dysregulated lipid metabolism [8]. Estrogens, especially E2, exert a protective role in the cardiovascular system... Therefore, menopause is associated with increased blood LDL-C levels and enhanced CVD risk [9].
Why this rating
Supported by multiple longitudinal studies (SWAN, WHILA) and mechanistic animal models.
Source
Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women
Seong‐Hee Ko et al. · Nutrients · 2020
DOI 10.3390/nu12010202
narrative_reviewCited 516×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Postmenopausal women should adopt a healthy dietary pattern (high in sea fish, seaweeds, dairy, cereals, vegetables, and fruits; low in fast food, animal fat, sweets, and fried food) to protect against dysregulated lipid metabolism, metabolic syndrome, and obesity.Moderate
- Increasing dietary protein intake to 1.0–1.2 g/kg/day helps compensate for skeletal muscle loss (sarcopenia) during weight loss in middle-aged and older women.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →